Lilly looks to Medtronic device to rescue GDNF in Parkinson's disease
This article was originally published in Scrip
Executive Summary
Lilly and Medtronic have agreed to an early-stage, drug-device collaboration in the area of Parkinson's disease. The deal aims to address a problem that has vexed others in the field of Parkinson's R&D and led to certain failures in clinical trials, the distribution of glial cell derived neurotrophic factor (GDNF) within a broad region of the brain.